ANTI-AGING CATALYST COMPOSITION CONTAINING A HIGH CONTENT BLEND OF COSMETIC ACIDS

Abstract

ANTI-AGING CATALYST COMPOSITION CONTAINING A HIGH CONTENT BLEND OF COSMETIC ACIDS An anti-aging catalyst composition includes a combination of cosmetically acceptable acids including at least three alpha-hydroxy acids, at least one beta-hydroxy acid, and one or more other cosmetically acceptable acids, the total amount of cosmetically acceptable acids in the anti-aging catalyst composition being in a range of about 5% to about 70%, each of the cosmetically acceptable acids in the anti-aging catalyst composition being in a range of about 0.1% to about 69%, wherein the anti-aging catalyst composition has a pH of about pH 1 to about pH 5.5. Figure for abstract: none

Description

Title of the invention: ANTI-AGING CATALYST COMPOSITION CONTAINING A MIXTURE WITH A HIGH CONTENT OF COSMETIC ACIDS FIELD OF THE INVENTION

[0001] The present invention relates generally to an anti-aging catalyst composition that is used as a catalyst prior to using anti-aging skin care compositions. The anti-aging catalyst enhances the anti-aging benefits of any anti-aging skin care routine, as demonstrated by improved skin properties, particularly on the face, for example, reducing wrinkles and fine lines on the forehead, providing better radiance than with the use of the anti-aging skin care composition or treatment regimen alone. BACKGROUND OF THE INVENTION

[0002] There are a variety of skin conditions that benefit from cosmetic products that can be applied to the skin to brighten the skin, reduce one or more of fine lines on the face, dullness, dryness, tightness, dark spots, and reduce the effects of acne or inflammatory lesions, improve skin scaling and renewal, and activate the proliferation of new cells in the skin, among other possible benefits. Many skin care products offer active ingredients that address one or more of these or other skin concerns, but there are challenges in providing products that contain high enough amounts of actives to provide the desired benefits.

[0003] Therefore, there is a need in the art for a composition that can increase the efficacy of anti-aging skin care products, particularly a composition and treatment regimens for modulating, improving, reducing or reversing the manifestation of dermatological signs of chronological aging, hormonal aging or photoaging of the skin.

[0004] The inventors have provided an anti-aging catalyst composition that is pre-applied to the skin prior to an anti-aging skin care composition or treatment regimen. The anti-aging catalyst composition used prior to the application of an anti-aging skin care composition or treatment regimen has been statistically and clinically demonstrated by the inventors to reduce visible fine lines and improve radiance immediately after initial application, and to provide a statistically significant reduction in the number of forehead wrinkles / fine lines at week 8 compared to the anti-aging skin care composition or treatment regimen applied alone. The anti-aging catalyst composition has been shown, through in vitro testing, to regulate the expression of genes related to skin aging. In certain embodiments, this composition may contribute to the improvement of tissue desquamation, epidermal development, cell cycle and cell division. BRIEF SUMMARY OF THE INVENTION

[0005] This summary is provided to introduce a selection of concepts in simplified form that are described more fully below in the detailed description of the invention. This summary is not intended to identify key features of the claimed subject matter, nor to be used as an aid in determining the scope of the claimed subject matter.

[0006] In various embodiments, the invention includes an anti-aging catalyst composition comprising: a mixture of cosmetically acceptable acids comprising at least one beta-hydroxy acid and at least three alpha-hydroxy acids, and one or more other cosmetically acceptable acids; and a cosmetically acceptable solvent comprising at least water, wherein the pH of the skin care composition is in a range of from about pH 3.6 to about pH 3.9.

[0007] The present disclosure describes exemplary embodiments in accordance with the general inventive concepts and is not intended to limit the scope of the invention in any way. Indeed, the invention as described in the patent specification is broader than, and not limited by, the exemplary embodiments presented herein, and the terms used herein have their full ordinary meanings. DETAILED DESCRIPTION OF THE INVENTION

[0008] In some embodiments, the anti-aging catalyst composition is in the form of a serum that may exclude oils, surfactants, and emulsifiers. In some embodiments, the anti-aging catalyst composition is in the form of an emulsion and thus comprises an oil phase that includes one or more oils and may include one or more surfactants or emulsifiers or combinations thereof. In some embodiments, the anti-aging catalyst composition is in the form of a gel.

[0009] In the context of the invention, a serum refers to a hydrophilic liquid composition formulated for topical application. A serum may optionally be free or essentially free of one or more of an oil, including an emollient, a wax, a surfactant, an emulsifier, a silicone oil, or a combination or all of the foregoing.

[0010] The terms “exclude”, “exempt” and “essentially free” mean that, although it is preferable that no excluded material be present in the composition of anti-aging catalyst, it is possible to have very small amounts of the excluded material in the anti-aging catalyst composition of the invention, provided that such amounts do not materially affect the advantageous properties of the anti-aging catalyst composition. In particular, "substantially free" means that the excluded material may be present in the anti-aging catalyst composition in an amount of less than 5%, or less than 4%, or less than 3%, or less than 2%, or less than 1%, or less than 0.1% by weight, or 0%, based on the total weight of the anti-aging catalyst composition.

[0011] In some embodiments, the anti-aging catalyst composition is free or essentially free of at least one active selected from the group consisting of ascorbic acid and other forms of vitamin C, ferulic acid, gallic acid, zinc pca, azelaic acid, chlorogenic acid and vitamin E, or a combination thereof.

[0012] In some embodiments, the anti-aging catalyst composition is free of or minimizes the use of non-renewable ingredients (e.g., mineral oil and petroleum-based ingredients) and ingredients that have a negative environmental impact (e.g., EDTA which mobilizes heavy metals). Thus, in some embodiments, the anti-aging catalyst composition is free or essentially free of ingredients selected from the group consisting of parabens, phthalates, cyclomethicones, a silicone, a mineral oil, petroleum-based ingredients, synthetic dyes, sulfates, a polyquaternium, microplastics, EDTA, silicone oils, mineral UV-blocking agents, organic UV-blocking agents, or a combination thereof.

[0013] As shown herein, the inventors have provided an anti-aging catalyst composition that is exemplified herein to unexpectedly impart one or more benefits, including, but not limited to: imparting, when applied to the skin prior to the application of an anti-aging skin care composition or treatment regimen, a statistically significant improvement in visible fine lines and radiance immediately after initial application; reducing the number of wrinkles / fine lines on the forehead at week 8 compared to the use of the anti-aging skin care composition or treatment regimen alone, which is shown in the study results included herein.

[0014] As also shown herein, the anti-aging catalyst composition exemplified herein unexpectedly confers one or more benefits including, but not limited to: when applied to the skin prior to the application of an anti-aging skin treatment composition or regimen, upregulation of the expression level of at least one gene associated with the regulation of cell division and at least one gene associated with the promotion of epidermal differentiation, and downregulation of the expression level of at least one gene associated with cornification, epidermal development and keratinization, and wherein the skin care composition acts to modulate, improve, reduce, or reverse the dermatological signs of chronological aging, hormonal aging or photoaging of the skin; and stimulates an increase in kallikrein, one or more gene expressions in the skin to which the anti-aging catalyst composition is applied followed by the application of a skin care composition comprising at least ascorbic acid or a derivative thereof, ferulic acid and tocopherol, compared to the skin care composition alone.

[0015] When combined with an anti-aging skin care composition that includes at least vitamin C, vitamin E, and ferulic acid (a CEF formulation), the anti-aging catalyst composition is capable of enhancing skin renewal and resurfacing benefits, as illustrated by its more pronounced impact on the functional pathways of skin cornification and epidermal development compared to the CEF treatment alone.

[0016] The inventors demonstrated, through nucleic acid analyses of full-thickness 3D reconstructed skin treatments, the ability of the anti-aging catalyst composition to significantly enhance skin renewal and resurfacing benefits. Compared to the use of an anti-aging skin care composition or treatment regimen alone, the anti-aging catalyst composition significantly amplifies the impact on the functional pathways of skin cornification and epidermal development. Importantly, while other treatments have also demonstrated these benefits, the anti-aging catalyst composition showed enhanced and distinctive efficacy, highlighting its particular importance in augmenting these crucial pathways.This is evidenced by the upregulation of expression levels of specific genes associated with the regulation of cell division and the promotion of epidermal differentiation, as highlighted in the provided examples and appendices. In addition, the results indicate a downregulation effect on the expression levels of genes associated with cornification, epidermal development, and keratinization, as detailed in the examples and appendices.

[0017] When combined with anti-aging routines, the anti-aging catalyst composition is capable of enhancing the anti-aging benefits of the skin, as illustrated by the reduction of fine lines and wrinkles on the forehead compared to the routines alone. Active ingredients in anti-aging routines combined with the anti-aging catalyst include, but are not limited to: antioxidants (including vitamins C, E, and their derivatives), chemical peels, retinols, niacinamide, panthenol, glycerin, squalane, ceramides, collagen, hyaluronic acid, peptides, plant and fruit extracts and sunscreens.

[0018] When combined with anti-aging routines, for example, but not limited to, antioxidant (AOX) treatments, AHA scrubs, retinol products, the anti-aging catalyst may enhance radiance immediately after application compared to anti-aging routines alone.

[0019] When combined with antioxidant formulations, the anti-aging catalyst may enhance AOX protection compared to the formulation alone.

[0020] Use of the anti-aging skin care composition may include application once a day, in the morning or at night, after cleansing and before treatment with an anti-aging skin care composition or regimen. The anti-aging skin care composition may be used year-round. Application includes a soaked makeup remover pad (1 drop) or is done directly by hand (8 to 10 drops). After application of the anti-aging skin care composition, the skin care regimen may be applied anytime, immediately up to 6 hours later.

[0021] The anti-aging skin care composition may be combined with anti-aging devices for home use (e.g., red light-based devices).

[0022] Accordingly, in various embodiments, the anti-aging catalyst composition is provided according to the detailed description which follows.

[0023] Cosmetically acceptable acids (acid-based skin actives)

[0024] The anti-aging catalyst composition includes a combination of cosmetically acceptable acids, the combination of cosmetically acceptable acids including a combination of at least three alpha-hydroxy acids, at least one beta-hydroxy acid, and one or more other cosmetically acceptable acids. In some embodiments, the anti-aging catalyst composition includes at least lactic acid, glycolic acid, mandelic acid, salicylic acid, and phytic acid. In some particular embodiments, the anti-aging catalyst composition includes only lactic acid, glycolic acid, mandelic acid, salicylic acid, and phytic acid.

[0025] The anti-aging catalyst composition is a water-based serum form that may be a rinse-off or leave-on formulation, wherein the anti-aging catalyst composition has a viscosity that is flowable when applied. In some embodiments, the anti-aging catalyst composition may be provided infused into a suitable substrate or contained in a dispenser.

[0026] In various embodiments, the total amount of cosmetically acceptable acid is present in a range of from about 1% to about 70%, or from about 5% to about 70%, or from about 5% to about 20%, or from about 5% to about 10%, or from about 5% to about 8%, by weight, based on the total weight of the anti-aging catalyst composition, and, if necessary, a neutralizing agent may be present to provide a pH in a range of from about pH 3.6 to about pH 9, or from about pH 1 to about pH 5.5, and in some embodiments from about pH 3.5 to pH 3.9. In some particular embodiments, the anti-aging catalyst composition has a pH of 3.7.

[0027] In various embodiments, if applicable, the neutralizing agent is present in a range of about 0.1% to about 5%, by weight, based on the total weight of the anti-aging catalyst composition. Alpha-hydroxy acids

[0028] The anti-aging catalyst composition comprises at least three alpha-hydroxy acids. In some particular embodiments, the at least three alpha-hydroxy acids include glycolic acid, lactic acid, and mandelic acid.

[0029] Suitable alpha-hydroxy acids include glycolic acid, lactic acid, mandelic acid, tartaric acid, citric acid, their ester derivatives, or a combination thereof. Examples of ester derivatives include lactic acid ester compounds, such as methyl lactate, ethyl lactate, butyl lactate, and similarly, glycolic acid, tartaric acid, mandelic acid, citric acid ester compounds. A particularly suitable alpha-hydroxy acid is lactic acid. Lactic acid, or 2-hydroxypropanoic acid, is provided in the composition to provide enhanced exfoliation of the skin. In addition, lactic acid also stimulates the production of glycosaminoglycans (GAGs) in the skin, which improves the barrier function and hydration of the skin.

[0030] The anti-aging catalyst composition may include a total alpha-hydroxy acid concentration of about 0.3% to about 69%, or about 0.3% to about 20%, or about 1% to about 15%, or about 2.5% to about 6%, or about 5.5%, or any suitable combination, subcombination, range, or subrange of these values ​​by weight, based on the weight of the anti-aging catalyst composition. However, those skilled in the art will understand that other ranges are within the scope of the invention. In some embodiments, the total amount of alpha-hydroxy acid present is not more than about 10%, or not more than about 6%. In various embodiments, each of the cosmetically acceptable acids in the anti-aging catalyst composition is present in a range of about 0.1% to about 69%, wherein the anti-aging catalyst composition has a pH of about pH 1 to about pH 5.5.

[0031] In certain particular embodiments, the alpha-hydroxy acid is present in a range of about 0.1% to about 5% and, in certain embodiments, is present at about 2.5%, lactic acid is present in a range of about 0.1% to about 5% and, in some embodiments, is present at about 2%, and mandelic acid is present in a range of about 0.1% to about 5% and, in some embodiments, is present at about 1% by weight of the anti-aging catalyst composition.

[0032] In some embodiments, the total amount of cosmetically acceptable alpha-hydroxy acids is present in a range of about 0.3% to about 15% and, in some embodiments, is about 5.5% by weight of the anti-aging catalyst composition.

[0033] Thus, any one or a combination of alpha-hydroxy acids, if any, may be present, by weight, based on the total weight of the anti-aging catalyst composition, in an amount of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, to about 15 or up to about 69%, by weight, based on the weight of the anti-aging catalyst composition, including increments and ranges therein. Beta-hydroxy acids

[0034] The anti-aging catalyst composition comprises at least one beta-hydroxy acid. In some particular embodiments, the anti-aging catalyst composition may include a beta-hydroxy acid comprising salicylic acid. In some particular embodiments, the anti-aging catalyst composition includes only a beta-hydroxy acid comprising salicylic acid.

[0035] The term "beta-hydroxy acid" refers to, according to the present invention, a carboxylic acid having a hydroxyl functional group and a carboxylic functional group separated by two carbon atoms. A beta-hydroxy acid may be present in the anti-aging catalyst composition in the form of the free acid and / or in the form of one of its associated salts (salts with an organic base or an alkali metal, in particular), in particular depending on the final pH imposed on the anti-aging catalyst composition.

[0036] Suitable beta-hydroxy acids include salicylic acid and its derivatives (including 5-n-octanoylsalicylic acid, salicylate, sodium salicylate, and willow extract), capryloylsalicylic acid, beta-hydroxybutanoic acid, propionic acid, beta-hydroxy beta-methylbutyric acid, carnitine tropic acid, and trethocanic acid, and combinations thereof.

[0037] And in some particular embodiments, the beta-hydroxy acid in the anti-aging catalyst composition may include at least one of salicylic acid and its derivatives (including 5-n-octanoylsalicylic acid, salicylate, sodium salicylate, and willow extract), capryloylsalicylic acid, beta- hydroxybutanoic acid, propionic acid, beta-hydroxy beta-methylbutyric acid, carnitine tropic acid and trethocanic acid.

[0038] The anti-aging catalyst composition includes a beta-hydroxy acid concentration in a range of from about 0.1% to and not more than about 2% beta-hydroxy acid, by weight, based on the total weight of the anti-aging catalyst composition. In some embodiments, the anti-aging catalyst composition may include up to and not more than about 2%, or about 1.9% beta-hydroxy acid. In some embodiments, the anti-aging catalyst composition may include up to and not more than about 1% beta-hydroxy acid. In some embodiments, the amount of beta-hydroxy acid, if any, is not more than about 0.40% to about 0.50%.

[0039] In some embodiments, the anti-aging catalyst composition may include from about 0.1% to about 1% beta-hydroxy acid, or from about 0.2% to about 2.0%, or from about 0.1% to about 1.5%, or from about 0.2% to about 1.5%, or from about 0.3% to about 1.0%, or from about 0.35% to about 0.75%, or from about 0.4% to about 0.5%, or is about 0.45%, or any suitable combination, subcombination, range or subrange of these values ​​by weight, based on the weight of the anti-aging catalyst composition. However, those skilled in the art will understand that other ranges are within the scope of the invention.

[0040] Thus, the at least one beta-hydroxy acid is present in the anti-aging catalyst composition in an amount of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, to about 2.0 or up to about 69%, by weight, based on the weight of the anti-aging catalyst composition, including increments and all intermediate ranges and sub-ranges. Other acids#; phytic acid

[0041] The anti-aging catalyst composition includes one or more other cosmetically acceptable acids that are not alpha- or beta-hydroxy acids.

[0042] In some embodiments, the anti-aging catalyst composition may include phytic acid. Phytic acid is also known as phytate and is a sextuple ester of inositol dihydrogen phosphate (specifically, of the myo isomer), also known as inositol hexakisphosphate (IP6) or inositol polyphosphate. At physiological pH, phosphates are partially ionized, resulting in the phytate anion. Phytic acid occurs naturally in plant seeds and is a storage form of phosphorus.

[0043] Phytic acid may be present in the anti-aging catalyst composition in an amount of about 0.5% to about 69%, or about 0.5% to about 15%, or about 0.5% to about 5%, and in some embodiments, about 1% to about 4%, and in some embodiments, about 1.5% to about 2.5%, or about 2%, or any suitable combination, subcombination, range or subrange of these values ​​by weight, based on the weight of the anti-aging catalyst composition. As exemplified herein, the phytic acid raw material may be provided at a dilution of 50% or otherwise as disclosed herein.

[0044] Thus, in various embodiments, phytic acid, if any, may be present in the anti-aging catalyst composition according to the disclosure, and each of the individual components in the ranges as described herein above, from about 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, to about 15% or up to about 69% by weight, based on the weight of the anti-aging catalyst composition, including intermediate increments and ranges. Amino acid

[0045] The anti-aging catalyst composition may include at least one amino acid. In some embodiments, the at least one amino acid may be selected from the group consisting of naturally occurring amino acids. In some embodiments, the at least one amino acid comprises taurine.

[0046] As non-limiting examples, the amino acids that may be used may be of natural or synthetic origin, in L, D or racemic form, and comprise at least one acid function selected, for example, from carboxylic acid, sulfonic acid, phosphonic acid and phosphoric acid functions. The amino acids may be in their neutral or ionic form. Polymeric forms are also useful, such as a polyarginine, a polylysine, etc. Additional non-limiting examples include basic amino acids comprising an additional amine function optionally included in a ring or in a ureido function.In some cases, amino acids that may be used include, but are not limited to, taurine, aspartic acid, glutamic acid, alanine, arginine, omithine, citrulline, asparagine, carnitine, cysteine, glutamine, glycine, histidine, lysine, isoleucine, leucine, methionine, N-phenylalanine, proline, serine, threonine, tryptophan, tyrosine, ornithine, citrulline, and valine.

[0047] In accordance with the various embodiments, the amount of amino acid, e.g., taurine, present in a composition according to the disclosure may range from about 0.1% to about 10%, or from about 0.2% to about 9%, or from about 0.5% to about 8%, or from about 0.8% to about 2%, or about 1%, or any suitable combination, subcombination, range, or subrange of these values ​​by weight, based on the weight of the composition. In some embodiments according to the disclosure, the composition includes at least about 0.5%, or at least about 1% of the at least one amino acid. In some embodiments according to the disclosure, the composition includes no more than about 1% of the at least one amino acid. amine. However, those skilled in the art will understand that other ranges fall within the scope of the invention.

[0048] Thus, any one or a combination of the amino acid, for example taurine, may be present, by weight, based on the total weight of the composition, or from about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5 to about 10.0 percent by weight, based on the weight of the anti-aging catalyst composition, including including increments and intermediate ranges. Solvents

[0049] The anti-aging catalyst composition includes water and optionally one or more water-soluble solvents.

[0050] In accordance with the various embodiments, water is present in the anti-aging catalyst composition in a range of about 10% to about 99%, or about 30% to about 95%, or about 50% to about 90%, or about 75% to about 85%, or any suitable combination, sub-combination, range or sub-range of these values ​​by weight, based on the total weight of the anti-aging catalyst composition. However, those skilled in the art will understand that other ranges are within the scope of the invention.

[0051] Thus, the water may be present, by weight, relative to the weight of the anti-aging catalytic composition, in an amount of approximately 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 to about 99 percent in weight, including increments and intermediate ranges.

[0052] The water used may be sterile demineralized water and / or floral water such as rose water, cornflower water, chamomile water or linden water, and / or natural thermal or mineral water such as, for example: Vittel water, Vichy basin water, Uriage water, La Roche-Posay water, La Bourboule water, Enghien-les-Bains water, Saint-Gervais-les-Bains water, Néris-les-Bains water, Allevar-les-Bains water, Digne water, Maizières water, Neyrac-les-Bains water, Lons-le-Saunier water, Eaux-Bonnes water, Rochefort water, Saint-Christau water, Les Fumades water, Tercis-les-Bains water or Avène water. The aqueous phase can also include reconstituted thermal water, i.e. water containing trace elements such as zinc, copper, magnesium, etc., restoring the characteristics of thermal water.

[0053] The pH of the anti-aging catalyst composition is corrected based on the amount of cosmetically acceptable acid to be within a range as set forth herein above. The pH is corrected to the desired value by the addition of a base (organic or inorganic), for example sodium hydroxide, potassium hydroxide or other suitable base, or a combination thereof. Water-soluble solvents

[0054] In some embodiments, the anti-aging catalyst composition may include at least one water-soluble solvent. The term “water-soluble solvent” is interchangeable with the term “water-miscible solvent” and refers to a compound that is liquid at 25°C and atmospheric pressure (760 mmHg), and that has a solubility of at least 50% in water under these conditions. In some cases, the water-soluble solvent has a solubility of at least 60%, 70%, 80%, or 90% in water under these conditions. Non-limiting examples of water-soluble solvents include, for example, glycerin, alcohols (e.g., selected from C1-C30, C1-C15, C1-C10, or C1-C4 alcohols), organic solvents, polyols, glycols, or mixtures thereof.

[0055] In certain particular embodiments according to the disclosure, where appropriate, a water-soluble solvent may include glycerin.

[0056] Examples of organic solvents that may be mentioned, without limitation, are the following organic solvents: ethyl alcohol, isopropyl alcohol, propyl alcohol, benzyl alcohol and phenylethyl alcohol, or glycols or glycol ethers such as, for example, monomethyl-, monoethyl- and monobutyl-ethers of ethylene glycol, propylene glycol or their ethers such as, for example, monomethyl ether of propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol as well as alkyl ethers of diethylene glycol, for example, monoethyl ether or monobutyl ether of diethylene glycol. Other suitable examples of organic solvents are ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propane diol and glycerin. Organic solvents can be volatile or non-volatile compounds.

[0057] Other non-limiting examples of water-soluble solvents include alkanols (polyhydric alcohols such as glycols and polyols) such as glycerin, 1,2,6-hexanetriol, trimethylolpropane, ethylene glycol, propylene glycol, diethylene glycol, butylene glycol, hexylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol, dipropylene glycol, 1,3-butanediol, 2,3-butanediol, 1,4-butanediol, 3-methyl-1,3-butanediol, 1,5-pentanediol, tetraethylene glycol, 1,6-hexanediol, 2-methyl-2,4-pentanediol, polyethylene glycol, 1,2,4-butanetriol, 1,2,6-hexanetriol, 2-butene-1,4-diol, 2-ethyl-1,3-hexanediol, 2-methyl-2,4-pentanediol, (caprylyl glycol), 1,2-hexanediol, 1,2-pentanediol and 4-methyl-1,2-pentanediol; alkyl alcohols having 1 to 4 carbon atoms such as ethanol, methanol, butanol, propanol and isopropanol; glycol ethers such as ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl etherglycol, ethylene glycol monomethyl ether acetate, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol mono-n-propyl ether, ethylene glycol mono-iso-propyl ether, diethylene glycol mono-iso-propyl ether, ethylene glycol mono-n-butyl ether, ethylene glycol mono-t-butyl ether, diethylene glycol mono-t-butyl ether, 1-methyl-l-methoxybutanol, propylene glycol monomethyl ether, propylene glycol monoethyl ether, propylene glycol mono-t-butyl ether, propylene glycol mono-n-propyl ether, propylene glycol mono-iso-propyl ether, dipropylene glycol monomethyl ether, dipropylene glycol monoethyl ether, dipropylene glycol mono-n-propyl ether and dipropylene glycol mono-iso-propyl ether; 2-pyrrolidone, N-methyl-2-pyrrolidone, l,3-dimethyl-2-imidazolidinone, formamide, acetamide, dimethyl sulfoxide, sorbitol, sorbitan, acetin, diacetin, triacetin, sulfolane, or mixtures thereof..

[0058] In accordance with the various embodiments, the amount of the at least one water-soluble solvent, if any, is from about 0.1% to about 25%, or from about 0.1% to about 2%, or from about 0.1% to about 1%, or from about 0.1% to about 0.8%, or from about 0.1% to about 0.5%, or from about 1% to about 20%, or from about 1% to about 10%, or from about 2% to about 8%, or any suitable combination, subcombination, range or subrange of these values ​​by weight, based on the total weight of the anti-aging catalyst composition. However, those skilled in the art will understand that other ranges are within the scope of the invention.In some embodiments, the anti-aging catalyst composition includes more than one water-soluble solvent, each water-soluble solvent being present in an amount as indicated above, wherein each different water-soluble solvent may be present in one of the ranges selected from the ranges indicated above.

[0059] Thus, each water-soluble solvent or combination of water-soluble solvents, if any, may be present by weight, based on the total weight of the anti-aging catalyst composition, in an amount of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 to about 25 weight percent, based on the weight of the anti-aging catalyst composition, including intermediate increments and ranges. OTHER INGREDIENTS

[0060] In some embodiments, one or more optional actives or other ingredients (hereinafter, "additives") may be present in the anti-aging catalyst composition.

[0061] In some embodiments, the anti-aging catalyst composition may include additional ingredients, including, but not limited to, pH adjusters, chelating agents, skin actives, humectants, agents penetrating into the skin, antioxidants, plant extracts, plant oils and butters, fragrances, fillers, powders, clays, pearling agents, odor absorbers, coloring materials and dyes, essential oils, vitamins, antimicrobials and preservatives, oils (of natural and synthetic origin, including but not limited to silicone oils, hydrocarbon-based oils, and waxes), as well as surfactants, emulsifiers, and combinations thereof. Non-limiting examples of some of these and other optional additional ingredients are provided below.

[0062] In some embodiments, the anti-aging catalyst composition excludes any one or a combination of pH adjusters, chelating agents, skin actives, humectants, skin penetrating agents, antioxidants, plant extracts, plant oils and butters, fragrances, fillers, powders, clays, pearlizing agents, odor absorbers, coloring materials and dyes, essential oils, vitamins, antimicrobials and preservatives, oils (naturally and synthetically derived, including but not limited to silicone oils, hydrocarbon-based oils, and waxes), as well as surfactants, emulsifiers, or a combination thereof.

[0063] In some embodiments, the anti-aging catalyst composition may include ingredients selected from: chelating agents, such as trisodium ethylenediamine disuccinate, ethylenediaminetetraacetic acid (EDTA), tetrasodium glutamate diacetate, tetrasodium etidronate, tetrasodium pyrophosphate, pentasodium ethylenediamine tetramethylenephosphonate, sodium staminate, and combinations thereof; humectants, such as acetamide MEA; dihydric and trihydric alcohols, such as glycerin, ethoxydiglycol, propylene glycol, propanediol, butylene glycol, dipropylene glycol, pentylene glycol, hexylene glycol, or a combination thereof; antimicrobials;antioxidants, including, but not limited to, phenolic compounds, such as chalcones, flavones, flavanones, flavanols, flavonols, dihydroflavonols, isoflavonoids, neoflavonoids, catechins, anthocyanidins, tannins, lignans, aurones, stilbenoids, curcuminoids, alkylphenols, betacyanins, capsacinoids, hydroxybenzoketones, methoxyphenols, naphthoquinones and phenolic terpenes, resveratrol, curcumin, pinoresinol, ferulic acid, hydroxytyrosol, cinnamic acid, caffeic acid, p-coumaric acid, baicalin (Scutellaria Baicalensis root extract), pine bark extract (Pinus Pinaster bark / bud extract), ellagic acid; hyaluronic acid and its derivatives; escin (also known as Aescin, a mixture of saponins with anti-inflammatory, vasoconstrictive and vasoprotective effects found in Aesculus hippocastanum; hydroxyacetophenone and 4-hydroxyacetophenone;and vitamins and vitamin derivatives, such as vitamin A, vitamin C (1-ascorbic acid, acetyl-; C (3-O-ethyl ascorbic acid), magnesium ascorbyl phosphate, sodium ascorbyl phosphate, tetrahexyldecyl ascorbate, ascorbylglucoside, or a combination thereof), vitamin E (tocopherol, alpha-tocopherol, beta-tocopherol, delta-tocopherol, gamma-tocopherol, alpha-tocotrienol, beta-tocotrienol, delta-tocotrienol, gamma-tocotrienol and their derivatives), vitamin D, calcium pantothenate; piroctone olamine; phenylethyl resorcinol; escin; retinol; citric acid; hydroxypropyl tetrahydropyrantriol; sequestrants; niacinamide, pyruvic acid; UV filters and UV enhancers; dispersants; ceramides; opacifiers; or one of their combinations.

[0064] In some embodiments, the one or more additives may be selected from fillers and / or clays of mineral or organic origin, natural or synthetic, to provide oil absorption or optical effects. The oil-absorbing fillers may provide a matte effect and a non-greasy feel to the skin. The optical effect fillers may provide a soft focus / veil / blurring effect to the skin, give the skin a more even appearance, reduce the appearance of skin imperfections or discolorations, or reduce the visibility of pores. A filler may include boron nitride, methyl methacrylate crosslinked polymer, mica, Zea mays (corn) starch, magnesium oxide, nylon-12, nylon-66, cellulose, polyethylene, talc, talc (and) methicone, talc (and) dimethicone, perlite, sodium silicate, pumice powder, PTFE,ammonium polyacryloyldimethyltaurate, polymethyl methacrylate, oryza sativa (rice) starch, aluminum starch octenylsuccinate, modified potato starch, alumina, calcium sodium borosilicate, magnesium carbonate, hydrated silica, dimethicone / vinyldimethicone crosspolymer, sodium carboxymethyl amdion, bismuth oxychloride, silica silylate, boron nitride, iron oxide, calcium carbonate, calcium sulfate (and) iron oxides, sodium aluminum potassium silicate, silica, silica (and) methicone, silica (and) dimethicone, polysilicone-22, polysilicone-8, polysilicone-11, a methyl methacrylate crosslinked polymer, a polymethylsilsesquioxane, a methylsilanol / silicate crosslinked polymer, a vinyldimethicone / methicone silsesquioxane crosslinked polymer,a crosslinked polymer of diphenyldimethicone / vinyl diphenyldimethicone silsesquioxane, and a styrene / acrylates copolymer, mica (and) lauroyllysine, synthetic fluorphlogopite (and) titanium dioxide (and) magnesium silicate (and) tin oxide, synthetic fluorphlogopite (and) titanium dioxide (and) tin oxide, titanium dioxide, or a combination thereof. Clays may include smectite, sodium smectite, calcium smectite, illite, chlorite, , vermiculite, atapulgite, phylosilicates, kaolinites, bentonite, hectorite, kaolin, silicates, magnesium aluminum silicate, montmorillonite (volcanic minerals), or a combination thereof.

[0065] In some embodiments, the additives may include an antimicrobial agent or a combination of antimicrobial agents and their salts, for example, including, but not limited to, the group consisting of chlorphenesin, caprylyl glycol, phenoxyethanol, caprylhydroxamic acid, benzoic acid, salicylic acid, benzyl alcohol, phenethyl alcohol, benzalkonium chloride, 4-hydroxyacetophenone, piroctone olamine, hexylglycerin, ethylhexylglycerin, octylglycerin, benzylglycerin, 3-heptoyl-2,2-propanediol, and 1,2-hexanediol, and pentylene glycol, and a combination thereof.

[0066] In some embodiments, the one or more additives may be selected from penetrants or penetration enhancers selected from ethoxydiglycol, dimethyl isosorbide, sodium dilauramidoglutamide lysine, polyglyceryl fatty acid ester, laurocapram, dipropylene glycol, propylene glycol, or a combination thereof.

[0067] In some embodiments, the additives may include a cosmetic oil or a combination of cosmetic oils. In some embodiments, the oil is generally immiscible with water. The oil may be selected from hydrocarbons, silicones, fatty alcohols, glycols, and vegetable oils. The oil may include a polar or non-polar oil or a combination thereof. In some embodiments, the oil may be selected from hydrocarbon-based oils derived from plants or of vegetable origin, mineral oil, ester oils, fatty alcohols containing from 12 to 26 carbon atoms, fatty acids containing from 12 to 26 carbon atoms, and vinylpyrrolidone copolymers, or a combination thereof.

[0068] In some embodiments, the additives may include one or a combination of nonionic, cationic, anionic or zwitterionic surfactant, or a combination thereof.

[0069] In some embodiments, the additives may include a thickener or a combination of thickeners, such as natural gums and synthetic polymers, for example, the thickener may be selected from the group consisting of starches (corn, rice, tapioca, potato), gums (xanthan, carrageenan, gellan, sclerotium, tarabiotech fermentation), hydroxypropyl guar, Ceratonia siliqua (locust bean) gum, an acrylates / C10-30 alkyl acrylate crosspolymer, a carbomer, an ammonium polyacryloyldimethyltaurate, an ammonium acryloyldimethyltaurate / steareth-25 methacrylate crosspolymer, and a polyacrylate-6 crosspolymer, or a combination thereof.

[0070] In some embodiments, the additives may include an alcohol or a combination of alcohols, for example, monohydric alcohols such as C1-C8 monohydric alcohols such as ethanol, propanol, butanol, isopropanol, isobutanol and benzyl alcohol, and phenylethyl alcohol, or a combination thereof.

[0071] Although the optional additives are given by way of example, it will be understood that other optional components compatible with suitable cosmetic applications known in the art may be used. Those skilled in the art will understand that any optional additives are present only to the extent that they, and their amount, do not materially adversely affect the fundamental and novel feature(s) of the claimed disclosure. Thus, in certain embodiments that include optional additives, these optional additives will not materially adversely affect the solubility of the skin actives of the anti-aging catalyst composition. And in certain embodiments that include optional additives, these optional additives will not materially adversely affect the stability or activity of the anti-aging catalyst composition.

[0072] For the avoidance of doubt, in certain embodiments, the anti-aging catalyst composition excludes any one or a combination of the foregoing listed active components and additives.

[0073] In some embodiments, the anti-aging catalyst composition is free or essentially free of at least one active selected from the group consisting of ascorbic acid and other forms of vitamin C, ferulic acid, gallic acid, zinc pca, azelaic acid, chlorogenic acid and vitamin E, or a combination thereof.

[0074] In some embodiments, the anti-aging catalyst composition is free of or minimizes the use of non-renewable ingredients (e.g., mineral oil and petroleum-based ingredients) and ingredients that have a negative environmental impact (e.g., EDTA which mobilizes heavy metals). Thus, in some embodiments, the anti-aging catalyst composition is free or essentially free of ingredients selected from the group consisting of parabens, phthalates, cyclomethicones, a silicone, a mineral oil, petroleum-based ingredients, synthetic dyes, sulfates, a polyquaternium, microplastics, EDTA, silicone oils, mineral UV-blocking agents, organic UV-blocking agents, or a combination thereof.

[0075] In accordance with the various embodiments, the amount of additives, e.g., actives and other components, when present in the anti-aging catalyst composition, may range from about 0.001% to about 50%, or from about 0.5% to about 30%, or from about 1.5% to about 20%, or from about 5% to about 15%, or any suitable combination, subcombination, range or subrange of such values ​​by weight, relative to the total weight of the anti-aging catalyst composition.

[0076] In some embodiments, one or more additives, alone or in combination, may be present in the anti-aging catalyst composition in an amount of from about 0.05% to about 50% by weight, from about 0.05% to about 25%, from about 0.1% to about 10%, from about 0.25% to about 5%, and from about 0.5% to about 3.5%, from about 0.05% to about 2.5% by weight, from about 0.1% to about 2%, from about 0.25% to about 1.5%, or from about 0.5% to about 1.25%, or any suitable combination, sub-combination, range or sub-range of these values ​​by weight, based on the weight of the anti-aging catalyst composition.

[0077] Thus, an additive or combination of additives, if any, may be present in the anti-aging catalyst composition, by weight, relative to the weight of the anti-aging catalyst composition, each or the combination being present in an amount of about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.70, 0.80, 0.90, 1.0, 2. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 to about 50 percent by weight, including intermediate increments and ranges. Example 1#: Raw Materials

[0078] The percentages of each ingredient as exemplified in the exemplary anti-aging catalyst composition embodiment are given as the amount of active ingredient, where the raw materials may be present in an amount equal to the amount of active, or if the raw material has an active concentration of less than 100%, the anti-aging catalyst composition includes the raw material that includes the active and a suitable solvent, where the active concentration in the raw material is provided herein below in Table 1. If a PM is not listed in the table, it should be assumed to have an active concentration of essentially 100%.

[0079] [Table 1]

[0080] TABLE 1: Select raw materials (including MPs with active concentrations below 100%) Ingredient Source Percentage of active (if less than 100%) GLYCOLIC ACID GUANGAN CHENGXIN CHE MICAL, CHEMOURS 70 LACTIC ACID CORBION PRODUTOS RENO VAVEIS 90 MANDEA IC ACID KUMAR ORGANICS PRODU CTS LIMITED PHYTICAL ACID TSUNO RICE FINE CHEMICA LS 50 SALICYL IC ACID JQC (HUAYIN) PHARMACEU TICAL, ALTA LABORATORI ES, NOVACYL TAURINE JIANGSU YUANYANG PHAR M SOLD QUIMDIS, QIANJIA NG YONGAN PHARMA

[0081] Example 2: Anti-aging catalyst composition of the invention

[0082] [Table 2]

[0083] TABLE 2: Composition of anti-aging catalyst of the invention Ingredient INV 1 Anti-aging catalyst CHLORPHENESIN 0.20 TAURINE 1.0 CAPRYLYL GLYCOL 0.20 ETHOXYDIGLYCOL 2.40 SODIUM HYDROXIDE 1.75 TETRASODIC GLUTAMATE DIACETATE 0.048 GLYCERIN 3.00 SALICYLIC ACID 0.20 WATER 83.70 GLYCOLIC ACID 2.5 LACTIC ACID 2.0 PHYTIC ACID 2.00 MANDELIC ACID 1.00

[0084] Note: the quantities represent the final concentration of active ingredient, although some active ingredients provided in the MP have an active ingredient concentration of less than 100%.

[0085] The above represents an exemplary embodiment of the invention; other embodiments are possible in accordance with the description set forth herein above.

[0086] Example 3: Taurine-induced nad+ stimulation studies

[0087] At-home micro-scrubs are a convenient and effective way for people to perform gentle chemical peels in the comfort of their own home. These skincare treatments involve the application of gentle exfoliating solutions to help improve skin texture, clarity, and radiance, without the need for professional intervention. At-home micro-scrubs are especially popular among those looking to treat mild skin concerns and achieve a fresher, smoother complexion. In general, AHAs, such as glycolic acid and lactic acid, work to exfoliate the outer layer of skin, while BHAs, such as salicylic acid, can penetrate deeper into pores, making them suitable for treating acne and clogged pores.The chemical solution gently dissolves dead skin cells, promoting cell renewal and stimulating the growth of new, healthier skin.

[0088] CE Ferulic is a cutting-edge antioxidant serum. This powerful formula combines 15% pure vitamin C (L-ascorbic acid), 1% vitamin E (alpha-tocopherol), and 0.5% ferulic acid. The unique blend of these ingredients provides superior protection against environmental stressors, such as UV rays and pollution, which can lead to premature aging and skin damage. The high concentration of vitamin C in CE Ferulic has been scientifically proven to neutralize free radicals, stimulate collagen synthesis, and brighten skin tone. 3,4 Regular use of CE Ferulic has been clinically shown to improve skin texture, reduce the appearance of fine lines and wrinkles, and promote a more even, radiant complexion.

[0089] The in vitro trials described herein examine a micro-scrub, CEFerulic and the combination of an anti-aging catalyst composition with the CEFerulic formula using reconstructed skin. The anti-aging catalyst composition may maximize the results, while amplifying the benefits, of at-home skin care. The note details the study on micro-scrub with the anti-aging catalyst composition, CEFerulic products and also the effects of a combination of the anti-aging catalyst composition with CE Ferulic. In addition, the formula of the anti-aging catalyst composition also included taurine as an active ingredient, which is believed to complement the function of the serum of the anti-aging catalyst composition by increasing the level of NAD+ in cells.

[0090] NAD+ plays an important role in cellular energy metabolism, as it forms reduced NADH, which provides reduction equivalents for the mitochondrial electron transport chain (ETC) to fuel oxidative phosphorylation. However, the role of NAD+ has expanded beyond its role as a coenzyme, as NAD+ and its metabolites also act as degradation substrates for a wide range of enzymes, such as sirtuins.l The role of NAD+ as a coenzyme in most metabolic pathways suggests that limitations in NAD+ could affect metabolic efficiency. Decreased NAD+ levels could therefore lead to the development of many diseases associated with aging. 1

[0091] Taurine is one of the most abundant free amino acids in mammalian tissues and its concentration in intracellular spaces reaches the millimolar level in some cell types. In a previous study, oral taurine supplementation was able to suppress UVB-induced wrinkle formation, which may be associated with the regulation of moisture content in the epidermis. The beneficial effects of taurine on skin aging may be attributed to its osmoregulatory role.2 Furthermore, dietary taurine supplementation improved MDA, GSSG / GSH and NAD+ / NADH levels in the diabetic precataract lens. 3 List of cited documents

[0092] 1. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. Jul 7, 2015; 22(1):31-53.

[0093] 2. Yoshimura T, Manabe C, Inokuchi Y, Mutou C, Nagahama T, Murakami S. Protective effect of taurine on UVB-induced skin aging in hairless mice. Biomed Pharmacother. Sep 2021 ; 141:111898.

[0094] 3. Obrosova IG, Stevens MJ. Effect of dietary taurine supplémentation on GSH and NAD(P)-redox status, lipid peroxidation, and energy metabolism in diabetic precataractous lens. Invest Ophthalmol Vis Sci. Mar 1999 ; 40(3):680-8.

[0095] ÉTUDES DE STIMULATION DE NAD+ INDUITE PAR LA TAURINE

[0096] Cell studies were conducted in which the effects of taurine and niacinamide on NAD+ production were evaluated when keratinocytes were cultured with these raw materials. Under all test conditions supplemented with active substances, the NAD+ of the cells increased compared to the untreated control. It was found that 0.2% niacinamide appeared to induce a higher level of NAD+ compared to 0.05% niacinamide. It was found that 0.05% taurine induced a comparable level of NAD+ compared to 0.2% niacinamide.

[0097] Taurine has been identified as an interesting active for skin care due to its potential benefits in boosting cellular energy. This report explores the effect of taurine supplementation with keratinocytes to understand its effect on increasing NAD+ levels in cells. This report demonstrates that taurine has a stimulatory effect on increasing NAD+ levels and is subject to future testing to fully understand the effect of taurine on cellular metabolism. In our in vitro study, we observed that CEF provides significant benefits to the cell cycle and cell division. When combined with an anti-aging catalyst composition, the treatment not only enhances the skin renewal and resurfacing benefits but also maintains the positive effects on the cell cycle and cell division.This is evident in the more pronounced impact on pathways related to skin cornification and epidermal development compared to single-type treatment.

[0098] Example 4: Tissue Morphology and Sequence Analysis Studies of arn

[0099] Tissue studies using 3D skin (Episkin full thickness skin tissue) were conducted, in which the tissue was cultured, then treated with an anti-aging catalyst composition (topical 5 mg / cm2) or 1 min, 5 min or 10 min, and then rinsed 3 times with PBS. Then, the tissues were incubated without any treatment, treated by scrubbing only, the tissues were treated with CEFerulic EU(Pure, topical 5 mg / cm2). The incubation time with topical application was 72 hours. The tissue was evaluated after sectioning and staining for macroscopic and microscopic effects and RNA sequence analyses were performed to evaluate the RNA levels of specific genes in the treated tissue.

[0100] The inventors treated the 3D skin with four different conditions: control, CEF treatment, anti-aging catalyst composition treatment, and a combination of CEF treatment and anti-aging catalyst composition. Then, we performed differential expression analysis and examined the biological pathways by gene ontology (GO) analysis.

[0101] The results, as presented on slides 4 to 11 of the appendix, reveal that, compared to the control, treatment with CEF resulted in the upregulation of 698 genes and the downregulation of 510 genes. Treatment with the anti-aging catalyst composition alone resulted in the upregulation of 16 genes and the downregulation of 11 genes. Notably, when CEF was combined with an anti-aging catalyst composition, we observed the upregulation of 1059 genes and the downregulation of 679 genes.

[0102] In our analysis of biological pathways, we observed that the cell cycle and cell division pathways were most significantly altered with CEF treatment, ranked among the two most impacted pathways. Epidermal comification and development pathways were also affected, but appeared outside the top 20 pathways. Referring again to the Appendix, the results present a list of cell cycle and cell division pathway genes that showed significant upregulation, and a summary of their functions is provided in the attached description. Interestingly, when tissues were treated with CEF+anti-aging catalyst composition, the order of impact of the pathways changed, with epidermal comification and development pathways taking priority over cell cycle and cell division. This highlights a more pronounced effect of CEF+anti-aging catalyst composition in promoting tissue sloughing, epidermal development, and turnover.

[0103] Description of the functions of genes modulated by CE Ferulic or the composition of anti-aging catalyst + CE Ferulic CE Ferulic upregulated:

[0104] KIF18B is a cell type-specific regulator of spindle orientation in the epidermis

[0105] BUB IB is a gene that encodes a kinase involved in spindle checkpoint function.

[0106] KIF14 is essential for localizing citron kinase to the mitotic spindle

[0107] CEP55 is essential for mitotic exit and cytokinesis.

[0108] ASPM is essential for maintaining orderly cell division

[0109] NCAPG2 regulates mitotic chromosomal architecture

[0110] SPAG5 is involved in the functional and dynamic regulation of mitotic spindles

[0111] PRC1 is a gene that codes for a protein involved in cytokinesis

[0112] KIF11 is an essential molecular motor protein in mitosis

[0113] CCNB1 regulates the cell transition from G2 phase to M phase

[0114] NUSAP1 regulates basal cell migration through activation of the Hedgehog signaling pathway

[0115] The ANLN gene encodes an actin-binding protein that plays a role in cell growth and migration, as well as in cytokinesis.

[0116] CENPE is a kinesin-like motor protein that accumulates in the G2 phase of the cell cycle

[0117] Anti-aging catalyst composition + upregulated Ferulic CE:

[0118] KIF18B is a cell type-specific regulator of spindle orientation in the epidermis

[0119] CDC20 acts as a regulatory protein that interacts with many other proteins at several times during the cell cycle.

[0120] PLK1 plays several critical roles in centrosome maturation, mitotic chromosome segregation, and cytokinesis

[0121] F0XM1 controls the expression of genes required for the G1 / S and G2 / M transition

[0122] BIRC5 is a family of inhibitor of apoptosis (IAP) genes, which encode negatively regulated proteins that prevent apoptotic cell death.

[0123] DLGAP5 is involved in several processes, including centrosome localization; kinetochore assembly; and mitotic spindle organization.

[0124] TPX2 is involved in mitotic spindle assembly during late prophase and early prometaphase

[0125] NCAPG2 is an essential participant of the condensin II complex involved in the process of chromosome cohesion and stabilization of mitosis

[0126] MKI67 regulates chromosome segregation and regulation of mitotic nuclear division.

[0127] CCNA2 promotes the transition via Gl / S and G2 / M.

[0128] KLK12 preserves skin barrier homeostasis through its roles in desquamation, antimicrobial defense, innate immune response, and barrier maintenance

[0129] SPRR2B encodes the keratinocyte cross-linked envelope protein

[0130] CDSN plays a vital role in the structural and functional integrity of the epidermis and the integrity of hair follicles

[0131] LCE1A belongs to the late cornified envelope (LCE) gene group within the epidermal differentiation complex (EDC)

[0132] SPRR2E is a gene encoding the keratinocyte cross-linked envelope protein

[0133] The TGM1 gene encodes a catalytic membrane-bound enzyme that functions in the formation of the epidermal horny cell envelope, composition of anti-aging catalyst + down-regulated ferulic CE:

[0134] DSG1 is expressed throughout the skin epidermis, promotes keratinocyte differentiation and suprabasal morphogenesis

[0135] DSC1 maintains the structure of the epidermis thanks to its adhesive function

[0136] KRT2 is involved in maintaining cellular integrity, regulating cell growth and migration, and protecting against apoptosis.

[0137] Example 5: Additional results of the study (see appendix)

[0138] REFERENCE SLIDES 5, 7 and 9 to 13 in the Appendix:

[0139] To investigate the main functional pathway of DEGs (differentially expressed genes), GO enrichment analysis was performed. The enrichment bubble plots of GO biological process level are shown. The vertical axis represents the pathway name, the horizontal axis represents the rich factor, and the dot size indicates the number of differentially expressed genes in this pathway. The color of the dots corresponds to different p-value ranges. Rich factor refers to the ratio of the number of differential genes (sample number) enriched in the pathway to the number of annotation genes (background number). A higher rich factor value indicates greater enrichment.

[0140] REFERENCE SLIDE 4 in the Appendix:

[0141] Principal component analysis (PCA) is widely used for data science and machine learning. It can tell us which dimensions of the original coordinate dominate the data. The first principal component (PCI) has the highest variance; the second principal component (PC2) has a second highest variance.

[0142] REFERENCE SLIDE 11 of the appendix:

[0143] “ / ” (slash): The slash represents a transition or progression from one phase to another. For example, "G1 / S" indicates the transition from the G1 phase to the S phase of the cell cycle, where DNA synthesis takes place. This means that the gene is active or appropriate during the transition between these phases.

[0144] "," (comma): The comma is used to separate different phases or different stages of the cell cycle that are relevant to the gene. For example, "G2 / M" indicates that the gene is active or relevant during the G2 phase and the following M phase (mitosis) of the cell cycle.

[0145] REFERENCE SLIDE 12 in the Appendix:

[0146] The following genes are identified as having the characteristics / functions described in general life science techniques.

[0147] KIF18B: Involved in metaphase and anaphase

[0148] BUB1B: Mainly associated with mitotic checkpoint control during metaphase and anaphase

[0149] KIF14: Plays a role in cytokinesis, particularly in the formation and function of the midbody during late cytokinesis

[0150] CEP55: Involved in cytokinesis and plays a role in midbody formation and function during late cytokinesis

[0151] ASPM: Associated with cytokinesis and plays a role in the regulation of cell division during late mitosis

[0152] NCAPG2: Involved in several stages of mitosis, including prophase, prometaphase, metaphase and anaphase

[0153] SPAG5 Plays a role in spindle organization and chromosome alignment during prophase, prometaphase, and metaphase

[0154] PRC1: Mainly associated with cytokinesis, particularly in the formation and function of the central spindle during late cytokinesis

[0155] KIF11: Involved in several stages of mitosis, including prophase, prometaphase, metaphase and anaphase

[0156] CCNB1: Associated with several stages of the cell cycle, including the G2 / M transition and the metaphase to anaphase transition during mitosis

[0157] NUSAP1: Mainly associated with mitotic spindle assembly during prophase, prometaphase and metaphase

[0158] ANLN: Involved in cytokinesis and plays a role in the formation and function of the contractile ring during late cytokinetics

[0159] CENPE: Plays a role in chromosome alignment and segregation during metaphase and anaphase.

[0160] It will be understood that, although these genes generally have understood roles in specific stages of cell division, their functions may extend beyond those mentioned or may be influenced by specific conditions and cell types, including unexpected involvement in skin properties and response to compositions such as those disclosed herein.

[0161] The articles "a" and "an" as used herein, mean one or more when applied to any feature in embodiments of the present invention described in the specification and claims. The use of "a" and "an" does not limit the meaning to a single feature, unless such a limitation is specifically stated. The article "the", "the", "the" preceding singular or plural nouns or noun phrases denotes a specified particular feature or specified particular features and may have a singular or plural connotation depending on the context in which it is used. The adjective "any", "all" means one, some or all indiscriminately, regardless of quantity.

[0162] “At least one,” as used herein, means one or more and thus includes individual components as well as mixtures / combinations.

[0163] The transitional phrases "comprising", "consisting essentially of" and "consisting of", when used in the appended claims, in their original and amended form, define the scope of the claims with respect to additional unmentioned elements or steps, if any, which are excluded from the scope of the claim(s). The term "comprising" is intended to be inclusive or broad and does not exclude any additional, unmentioned element, process, step or material. The phrase "consisting of" excludes any element, step or material other than those specified in the claims and, in the latter case, impurities ordinarily associated with the specified material(s). The phrase "consisting essentially of" limits the scope of a claim to the specified elements, steps or material(s) and to those which do not materially affect the fundamental and novel feature(s) of the claimed invention. All methods and materials described herein that incorporate the present invention may, in alternative embodiments, be more specifically defined by any of the transitional phrases "comprising", "consisting essentially of", and "consisting of".

[0164] Other than the working examples, or unless otherwise indicated, all numbers expressing amounts of ingredients and / or reaction conditions preceded by the word "about" should be understood to mean within 10% of the number indicated (e.g., "about 10%" means 9% to 11% and "about 2%" means 1.8% to 2.2%).

[0165] All percentages and ratios are, unless otherwise indicated, calculated by weight. All percentages are, unless otherwise indicated, calculated based on the total composition. In general, unless otherwise expressly indicated herein, “weight” or “amount” as used herein with respect to the percentage amount of an ingredient refers to the amount of raw material comprising the ingredient, wherein the raw material may be described herein as comprising less than and up to 100% of the ingredient’s activity. Accordingly, the weight percentage of an active ingredient in a composition is represented as the amount of raw material containing the active ingredient that is used and may or may not reflect the final percentage of the active, wherein the final percentage of the active depends on the weight percentage of the active ingredient in the raw material.

[0166] All ranges and amounts given herein are intended to include subranges and amounts using any disclosed point as a boundary. Thus, a range of "1% to 10%, such as 2% to 8%, such as 3% to 5%" is intended to encompass ranges of "1% to 8%," "1% to 5%," "2% to 10%," and so on. All figures, amounts, ranges, etc. are intended to be modified by the term "about," whether or not expressly stated. Similarly, a given range of "about 1% to 10%" is intended to have both its 1% and 10% boundaries modified by the term "about." Furthermore, it is understood that when an amount of a component is given, it is intended to mean the amount of the active ingredient unless specifically stated otherwise.

[0167] Although the numerical ranges and parameters within the general scope of the disclosure are approximations, unless otherwise indicated, the numerical values ​​presented in the specific examples are reported as accurately as possible. However, any numerical value inherently contains certain errors necessarily resulting from the standard deviation observed in their respective test measurements. The following example serves to illustrate embodiments of the present disclosure without, however, being limiting in nature.

[0168] Although the invention has been described with reference to a preferred embodiment, those skilled in the art will understand that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. Furthermore, numerous modifications may be made to adapt a particular situation or subject matter to the teachings of the invention without departing from its essential scope. Accordingly, the invention is not limited to the particular embodiment disclosed as the best mode contemplated for carrying out this invention, but the invention will include all embodiments falling within the scope of the appended claims.

Claims

Claims

1. An anti-aging catalyst composition comprising: a mixture of cosmetically acceptable acids comprising at least one beta-hydroxy acid and at least three alpha-hydroxy acids, and one or more other cosmetically acceptable acids; and a cosmetically acceptable solvent comprising at least water, wherein the pH of the skin care composition is in a range of from about pH 3.6 to about pH 3.

9.

2. An anti-aging catalyst composition according to claim 1, comprising at least one amino acid comprising at least taurine.

3. An anti-aging catalyst composition according to claim 1 or 2, wherein the one or more other cosmetically acceptable acids which are not an alpha- or beta-hydroxy acid include at least phytic acid.

4. An anti-aging catalyst composition according to any preceding claim, wherein the mixture of cosmetically acceptable acids includes at least salicylic acid, glycolic acid, lactic acid, mandelic acid and phytic acid.

5. The anti-aging catalyst composition of claim 4, wherein the mixture of cosmetically acceptable acids which includes at least salicylic acid, glycolic acid, lactic acid, mandelic acid and phytic acid is present in the composition in a total amount of 7.7%, by weight, based on the total weight of the anti-aging catalyst composition.

6. An anti-aging catalyst composition according to any preceding claim, wherein the total amount of cosmetically acceptable acid is present in a range of about 1% to about 70%.

7. An anti-aging catalyst composition according to any preceding claim, wherein each of the cosmetically acceptable acids in the anti-aging catalyst composition is present in a range of about 0.1% to about 69%, and wherein the anti-aging catalyst composition has a pH of about pH 1 to about pH 5.

5.

8. An anti-aging catalyst composition according to any preceding claim, wherein the anti-aging catalyst composition excludes any one or a combination of pH adjusters, chelating agents, skin actives, humectants, skin penetrating agents, antioxidants, plant extracts, plant oils and butters, perfumes, fillers, powders, clays, pearlizing agents, odor absorbers, coloring materials and dyes, essential oils, vitamins, antimicrobials and preservatives, oils (of natural and synthetic origin, including but not limited to silicone oils, hydrocarbon-based oils and waxes), as well as surfactants, emulsifiers, or a combination thereof.

9. An anti-aging catalyst composition according to any preceding claim, wherein the anti-aging catalyst composition excludes any one or a combination of parabens, phthalates, cyclomethicones, silicone, mineral oil, petroleum-based ingredients, synthetic dyes, sulfates, polyquaternium, microplastics, EDTA, silicone oils, mineral UV-blocking agents, organic UV-blocking agents, or a combination thereof.

10. An anti-aging catalyst composition according to any preceding claim, wherein the anti-aging catalyst composition excludes any one or a combination of ascorbic acid and other forms of vitamin C, ferulic acid, gallic acid, zinc pca, azelaic acid, chlorogenic acid, and vitamin E, or a combination thereof.